questionsmedicales.fr
Composés chimiques organiques
Amidines
Guanidines
Biguanides
Biguanides : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Diabète de type 2
Glycémie
HbA1c
Résistance à l'insuline
Test de tolérance au glucose
HOMA-IR
Diabète
Symptômes
Hyperglycémie
Biguanides
Glycémie
HbA1c
Symptômes
5
Biguanides
Effets secondaires
Gastro-intestinal
Hypoglycémie
Symptômes
Diabète
Acidose lactique
Symptômes
Biguanides
Diabète
Complications
Symptômes
Biguanides
Appétit
Perte de poids
Prévention
5
Prévention
Diabète de type 2
Mode de vie sain
Facteurs de risque
Obésité
Diabète
Poids corporel
Résistance à l'insuline
Diabète
Activité physique
Prévention
Diabète
Contrôles médicaux
Diabète
Prévention
Traitements
5
Biguanides
Insuline
Glucose
Metformine
Biguanides
Diabète de type 2
Biguanides
Diabète de type 2
Traitement
Metformine
Dosage
Diabète
Biguanides
Antidiabétiques
Traitement combiné
Complications
5
Complications
Diabète
Maladies cardiovasculaires
Prévention
Complications
Diabète
Neuropathie diabétique
Symptômes
Diabète
Néphropathie
Diabète
Complications
Examens médicaux
Complications
Diabète
Facteurs de risque
5
Facteurs de risque
Diabète
Obésité
Hérédité
Diabète
Facteurs de risque
Tabagisme
Diabète
Facteurs de risque
Alimentation
Diabète
Facteurs de risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Biguanides : Questions médicales les plus fréquentes",
"headline": "Biguanides : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Biguanides : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-17",
"dateModified": "2025-04-11",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Biguanides"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Guanidines",
"url": "https://questionsmedicales.fr/mesh/D006146",
"about": {
"@type": "MedicalCondition",
"name": "Guanidines",
"code": {
"@type": "MedicalCode",
"code": "D006146",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D02.078.370"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Buformine",
"alternateName": "Buformin",
"url": "https://questionsmedicales.fr/mesh/D002026",
"about": {
"@type": "MedicalCondition",
"name": "Buformine",
"code": {
"@type": "MedicalCode",
"code": "D002026",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D02.078.370.141.075"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Chlorhexidine",
"alternateName": "Chlorhexidine",
"url": "https://questionsmedicales.fr/mesh/D002710",
"about": {
"@type": "MedicalCondition",
"name": "Chlorhexidine",
"code": {
"@type": "MedicalCode",
"code": "D002710",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D02.078.370.141.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Metformine",
"alternateName": "Metformin",
"url": "https://questionsmedicales.fr/mesh/D008687",
"about": {
"@type": "MedicalCondition",
"name": "Metformine",
"code": {
"@type": "MedicalCode",
"code": "D008687",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D02.078.370.141.450"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Phenformine",
"alternateName": "Phenformin",
"url": "https://questionsmedicales.fr/mesh/D010629",
"about": {
"@type": "MedicalCondition",
"name": "Phenformine",
"code": {
"@type": "MedicalCode",
"code": "D010629",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D02.078.370.141.700"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Proguanil",
"alternateName": "Proguanil",
"url": "https://questionsmedicales.fr/mesh/D002727",
"about": {
"@type": "MedicalCondition",
"name": "Proguanil",
"code": {
"@type": "MedicalCode",
"code": "D002727",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D02.078.370.141.710"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Biguanides",
"alternateName": "Biguanides",
"code": {
"@type": "MedicalCode",
"code": "D001645",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Liam Good",
"url": "https://questionsmedicales.fr/author/Liam%20Good",
"affiliation": {
"@type": "Organization",
"name": "Pathobiology and Population Sciences, The Royal Veterinary College, London, England."
}
},
{
"@type": "Person",
"name": "Alan A Rogers",
"url": "https://questionsmedicales.fr/author/Alan%20A%20Rogers",
"affiliation": {
"@type": "Organization",
"name": "Flintshire, North Wales, UK."
}
},
{
"@type": "Person",
"name": "Manuel D Gahete",
"url": "https://questionsmedicales.fr/author/Manuel%20D%20Gahete",
"affiliation": {
"@type": "Organization",
"name": "Maimonides Institute for Biomedical Research of Cordoba, Córdoba, Spain."
}
},
{
"@type": "Person",
"name": "Justo P Castaño",
"url": "https://questionsmedicales.fr/author/Justo%20P%20Casta%C3%B1o",
"affiliation": {
"@type": "Organization",
"name": "Maimonides Institute for Biomedical Research of Cordoba, Córdoba, Spain."
}
},
{
"@type": "Person",
"name": "Raúl M Luque",
"url": "https://questionsmedicales.fr/author/Ra%C3%BAl%20M%20Luque",
"affiliation": {
"@type": "Organization",
"name": "Maimonides Institute for Biomedical Research of Cordoba, Córdoba, Spain."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Comparison of the Safety of Prednisone Plus Dipyridamole Versus Prednisone Plus Valsartan in the Treatment of Children with Primary Nephrotic Syndrome.",
"datePublished": "2024-08-20",
"url": "https://questionsmedicales.fr/article/39423092",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": null
}
},
{
"@type": "ScholarlyArticle",
"name": "The Effects of Daily Prednisone and Tocilizumab on Hemoglobin A",
"datePublished": "2023-01-25",
"url": "https://questionsmedicales.fr/article/36383175",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/art.42405"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prednisone vs methotrexate in treatment naïve cardiac sarcoidosis.",
"datePublished": "2023-01-14",
"url": "https://questionsmedicales.fr/article/36640249",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12350-022-03171-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial.",
"datePublished": "2022-09-11",
"url": "https://questionsmedicales.fr/article/36099670",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejca.2022.08.002"
}
},
{
"@type": "ScholarlyArticle",
"name": "Successfully treated with siltuximab and prednisone in a 7-year-old girl with",
"datePublished": "2024-07-09",
"url": "https://questionsmedicales.fr/article/39044832",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2024.1414573"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés chimiques organiques",
"item": "https://questionsmedicales.fr/mesh/D009930"
},
{
"@type": "ListItem",
"position": 3,
"name": "Amidines",
"item": "https://questionsmedicales.fr/mesh/D000578"
},
{
"@type": "ListItem",
"position": 4,
"name": "Guanidines",
"item": "https://questionsmedicales.fr/mesh/D006146"
},
{
"@type": "ListItem",
"position": 5,
"name": "Biguanides",
"item": "https://questionsmedicales.fr/mesh/D001645"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Biguanides - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Biguanides",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Biguanides",
"description": "Comment diagnostiquer le diabète de type 2 ?\nQuels tests sont utilisés pour évaluer la résistance à l'insuline ?\nQuels symptômes indiquent un diabète non contrôlé ?\nComment évaluer l'efficacité des biguanides ?\nQuels sont les critères de diagnostic du diabète ?",
"url": "https://questionsmedicales.fr/mesh/D001645?mesh_terms=Prednisone#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Biguanides",
"description": "Quels sont les effets secondaires des biguanides ?\nComment reconnaître une hypoglycémie ?\nQuels symptômes peuvent indiquer une acidose lactique ?\nQuels signes indiquent une mauvaise gestion du diabète ?\nComment les biguanides affectent-ils l'appétit ?",
"url": "https://questionsmedicales.fr/mesh/D001645?mesh_terms=Prednisone#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Biguanides",
"description": "Comment prévenir le diabète de type 2 ?\nQuels facteurs de risque sont modifiables ?\nComment le poids corporel influence-t-il le diabète ?\nQuel rôle joue l'activité physique dans la prévention ?\nLes contrôles médicaux réguliers sont-ils importants ?",
"url": "https://questionsmedicales.fr/mesh/D001645?mesh_terms=Prednisone#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Biguanides",
"description": "Comment les biguanides agissent-ils ?\nQuels sont les principaux biguanides utilisés ?\nQuand commencer un traitement par biguanides ?\nQuels sont les dosages habituels de metformine ?\nLes biguanides peuvent-ils être combinés avec d'autres médicaments ?",
"url": "https://questionsmedicales.fr/mesh/D001645?mesh_terms=Prednisone#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Biguanides",
"description": "Quelles sont les complications du diabète mal contrôlé ?\nComment prévenir les complications liées au diabète ?\nQuels sont les signes d'une neuropathie diabétique ?\nComment le diabète affecte-t-il la santé rénale ?\nQuels examens sont nécessaires pour surveiller les complications ?",
"url": "https://questionsmedicales.fr/mesh/D001645?mesh_terms=Prednisone#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Biguanides",
"description": "Quels sont les principaux facteurs de risque du diabète ?\nL'hérédité joue-t-elle un rôle dans le diabète ?\nComment le stress influence-t-il le diabète ?\nLe tabagisme est-il un facteur de risque ?\nQuel impact a l'alimentation sur le risque de diabète ?",
"url": "https://questionsmedicales.fr/mesh/D001645?mesh_terms=Prednisone#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer le diabète de type 2 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par des tests de glycémie, comme la glycémie à jeun ou l'HbA1c."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer la résistance à l'insuline ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le test de tolérance au glucose et l'indice HOMA-IR sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un diabète non contrôlé ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent soif excessive, urination fréquente et fatigue persistante."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité des biguanides ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par la réduction de la glycémie et l'amélioration de l'HbA1c."
}
},
{
"@type": "Question",
"name": "Quels sont les critères de diagnostic du diabète ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères incluent une glycémie à jeun ≥ 7 mmol/L ou HbA1c ≥ 6,5%."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des biguanides ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des troubles gastro-intestinaux et des douleurs abdominales."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une hypoglycémie ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent tremblements, sueurs, confusion et palpitations."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer une acidose lactique ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue extrême, douleurs musculaires et respiration rapide."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une mauvaise gestion du diabète ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des infections fréquentes, des plaies qui guérissent lentement et des troubles de la vision."
}
},
{
"@type": "Question",
"name": "Comment les biguanides affectent-ils l'appétit ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les biguanides peuvent réduire l'appétit, contribuant ainsi à la perte de poids chez certains patients."
}
},
{
"@type": "Question",
"name": "Comment prévenir le diabète de type 2 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice régulier, aide à prévenir le diabète."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont modifiables ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'obésité, le manque d'activité physique et une alimentation déséquilibrée sont modifiables."
}
},
{
"@type": "Question",
"name": "Comment le poids corporel influence-t-il le diabète ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un excès de poids augmente la résistance à l'insuline, augmentant le risque de diabète."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'activité physique dans la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'activité physique régulière améliore la sensibilité à l'insuline et aide à contrôler le poids."
}
},
{
"@type": "Question",
"name": "Les contrôles médicaux réguliers sont-ils importants ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des contrôles réguliers aident à détecter précocement le diabète et à gérer les risques."
}
},
{
"@type": "Question",
"name": "Comment les biguanides agissent-ils ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils diminuent la production de glucose par le foie et augmentent la sensibilité à l'insuline."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux biguanides utilisés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La metformine est le biguanide le plus couramment prescrit pour le diabète de type 2."
}
},
{
"@type": "Question",
"name": "Quand commencer un traitement par biguanides ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement commence généralement après un diagnostic de diabète de type 2 et un échec des changements de mode de vie."
}
},
{
"@type": "Question",
"name": "Quels sont les dosages habituels de metformine ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les doses varient de 500 mg à 2000 mg par jour, selon la tolérance et la réponse du patient."
}
},
{
"@type": "Question",
"name": "Les biguanides peuvent-ils être combinés avec d'autres médicaments ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent être combinés avec d'autres antidiabétiques pour un meilleur contrôle glycémique."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications du diabète mal contrôlé ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des maladies cardiovasculaires, des neuropathies et des problèmes rénaux."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications liées au diabète ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un bon contrôle glycémique et des examens réguliers aident à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les signes d'une neuropathie diabétique ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des picotements, des engourdissements et des douleurs dans les membres."
}
},
{
"@type": "Question",
"name": "Comment le diabète affecte-t-il la santé rénale ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diabète peut entraîner une néphropathie, affectant la fonction rénale et provoquant des complications."
}
},
{
"@type": "Question",
"name": "Quels examens sont nécessaires pour surveiller les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens réguliers de la fonction rénale, des pieds et des yeux sont essentiels."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque du diabète ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'obésité, l'âge avancé, l'hérédité et le mode de vie sédentaire."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle dans le diabète ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un antécédent familial de diabète augmente le risque de développer la maladie."
}
},
{
"@type": "Question",
"name": "Comment le stress influence-t-il le diabète ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress peut affecter la glycémie et la gestion du diabète, augmentant le risque de complications."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme augmente le risque de diabète et de complications cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Quel impact a l'alimentation sur le risque de diabète ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en sucres et en graisses saturées augmente le risque de diabète."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 11/04/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Pathobiology and Population Sciences, The Royal Veterinary College, London, England.
Publications dans "Biguanides" :
3 publications dans cette catégorie
Affiliations :
Flintshire, North Wales, UK.
Publications dans "Biguanides" :
3 publications dans cette catégorie
Affiliations :
Maimonides Institute for Biomedical Research of Cordoba, Córdoba, Spain.
Department of Cell Biology, Physiology, and Immunology, University of Córdoba, Córdoba, Spain.
Reina Sofia University Hospital, Córdoba, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición, Córdoba, Spain.
Publications dans "Biguanides" :
3 publications dans cette catégorie
Affiliations :
Maimonides Institute for Biomedical Research of Cordoba, Córdoba, Spain.
Department of Cell Biology, Physiology, and Immunology, University of Córdoba, Córdoba, Spain.
Reina Sofia University Hospital, Córdoba, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición, Córdoba, Spain.
Publications dans "Biguanides" :
3 publications dans cette catégorie
Affiliations :
Maimonides Institute for Biomedical Research of Cordoba, Córdoba, Spain.
Department of Cell Biology, Physiology, and Immunology, University of Córdoba, Córdoba, Spain.
Reina Sofia University Hospital, Córdoba, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición, Córdoba, Spain.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
University of Colorado Hospital, Aurora, CO, USA.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
Institut de Chimie de Nice UMR7272, Parc Valrose, Université Côte d'Azur, Nice, France.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
Institut de Chimie de Nice UMR7272, Parc Valrose, Université Côte d'Azur, Nice, France.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
Institut de Chimie de Nice UMR7272, Parc Valrose, Université Côte d'Azur, Nice, France.
Department of Chemical and Biochemical Sciences, Mohammed VI Polytechnic University (UM6P), Ben Guerir, Morocco.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
Antibiotics, Biocides, Residues and Resistance Unit, Fougères Laboratory, French Agency for Food, Environmental and Occupational Health & Safety (ANSES), Fougères, France.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
Antibiotics, Biocides, Residues and Resistance Unit, Fougères Laboratory, French Agency for Food, Environmental and Occupational Health & Safety (ANSES), Fougères, France.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
Antibiotics, Biocides, Residues and Resistance Unit, Fougères Laboratory, French Agency for Food, Environmental and Occupational Health & Safety (ANSES), Fougères, France.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
Medical Mycology Research Center.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
Medical Mycology Research Center.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
R&D-Safety Science Research, Kao Corporation.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
R&D-Safety Science Research, Kao Corporation.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
Medical Mycology Research Center.
Molecular Chirality Research Center, Chiba University.
Plant Molecular Science Center, Chiba University.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
Medical Mycology Research Center.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
Département de Biochimie et Médecine Moléculaire, and CRCHUM-Faculté de Médecine, Université de Montréal, Montreal, QC, Canada. g.ferbeyre@umontreal.ca.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
Département de Chimie-Faculté des Arts et des Sciences, Université de Montréal, 2900 Edouard Montpetit, Succursale Centre-Ville, CP 6128, Montreal, QC, H3C3J7, Canada. ar.schmitzer@umontreal.ca.
Publications dans "Biguanides" :
In recent years, the incidence of pediatric nephrotic syndrome (NS) has been increasing, and timely and effective treatment is critical to protect the health of children with NS. This study is an atte...
Two hundred pediatric cases of NS were selected as the research participants, including 109 cases (group A) receiving Pred + DIP and 91 cases (group B) receiving Pred + VAL. The clinical efficacy, adv...
No statistically significant differences were found between groups in terms of clinical efficacy, incidence of adverse reactions and renal function (P > .05). After receiving the corresponding treatme...
Both Pred + DIP and Pred + VAL combination therapies can be used for the treatment of pediatric NS, with the former contributing to more obviously enhanced coagulation and immune functions, and the la...
To study the longitudinal effects of both glucocorticoids and tocilizumab, an interleukin-6 receptor inhibitor, on hemoglobin A...
We analyzed patients with complete data from the Giant Cell Arteritis Clinical Research Study (GiACTA) to investigate the impact of both glycemic and nonglycemic factors on changes in HbA...
In 209 patients, the median HbA...
Tocilizumab treatment was associated with a substantial reduction in HbA...
Side effects limit the long-term use of glucocorticoids in cardiac sarcoidosis (CS), and methotrexate has gained attention as steroid sparing agent although the supporting evidence is poor. This study...
In this retrospective cohort study, 61 newly diagnosed and treatment naïve CS patients commenced treatment with prednisone (N = 21), methotrexate (N = 30) or prednisone and methotrexate (N = 10) betwe...
Significant suppression of cardiac FDG uptake occurred in CS patients after 6 months of prednisone, methotrexate or combination therapy. There were no significant differences in clinical outcomes duri...
We aimed to compare the efficacy and safety of maintaining or withdrawing abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-resistant prostate cancer who had experienced...
Phase II, randomised, open-label study conducted in patients with metastatic castration-resistant prostate cancer who were asymptomatic or mildly symptomatic. After open-label treatment with AAP, pati...
A total of 148 patients were included in open-label treatment with AAP, and of them, 94 patients were randomised to receive either docetaxel plus AAP (intervention group; n = 47) or docetaxel plus pre...
Our results indicate that the therapeutic strategy of maintaining AAP added to docetaxel in chemotherapy-naïve patients who have experienced cancer progression to AAP treatment should not be further e...
NCT02036060 https://clinicaltrials.gov/ct2/show/NCT02036060....
Dedicator of cytokinesis 8 (DOCK8) deficiency represents a primary immunodeficiency with a wide range of clinical symptoms, including recurrent infections, atopy, and increased malignancy risk. This s...
Retroperitoneal fibrosis (RPF) is a rare autoimmune disease with fibrous tissue growth and inflammation in retroperitoneum. Its current treatments involve long-term uptake of glucocorticoids (e.g., pr...
We surveyed gene-disease-drug databases and discovered that mammalian target of rapamycin (mTOR) was a key signalling protein in RPF and the mTOR inhibitor compound sirolimus affected many RPF pathway...
With the combined therapy, fibrous tissue shrunk about by half, markers of acute inflammation reduced by 70% and most patients with abnormal kidney functions had them restored to normal range. Molecul...
Our combined therapy resulted in significant fibrosis remission and an overall regression of the immune system towards healthy states, while achieving good tolerance. We concluded that this new therap...
In recurrent implantation failure patients (RIF), the main criteria for diagnosis of chronic endometritis, is the presence of plasma cells CD138...
Cancer-related mortality rates among kidney transplant recipients (KTR) are high, but these patients have largely been excluded from trials of immune checkpoint inhibitors because of immunosuppression...
Adult KTR with advanced melanoma or basal, cutaneous squamous, or Merkel cell carcinomas were eligible. Immunosuppression was standardized to TACRO (serum trough 2-5 ng/mL) + PRED 5 mg once daily. Pat...
Among eight evaluable patients, none met the trial's primary end point. All eight patients experienced PD on NIVO + TACRO + PRED; TRAL occurred in one patient. Six patients then received IPI + NIVO + ...
In most KTR with advanced skin cancer, TACRO + PRED provides insufficient allograft protection and compromises immune-mediated tumor regression after administration of NIVO ± IPI. Elevated dd-cfDNA le...
Ruxolitinib is a safe and effective therapy of myeloproliferative neoplasm-associated (MPN) myelofibrosis. However, often there are dose reductions and/or therapy interruptions because of therapy-rela...
Glucocorticoids are 1 of the primary treatments in paediatric kidney transplantation. The aims of this study were: (i) to build a population pharmacokinetics (PPK) model of free prednisolone, which is...
Ninety-seven samples were obtained from 39 paediatric kidney transplant recipients (aged 3.4-17.2 years) in order to investigate prednisone PPK. We selected children receiving oral prednisone as part ...
A 1-compartment model best described prednisolone concentrations. Large IIV was observed as prednisolone was undetectable at H12 in some patients but could still be detected at H24 in others. Both bod...
This study is the first analysis of prednisolone PPK in kidney-transplanted children. Some of the IIV in the PK parameters was explained by bodyweight and ciclosporin cotreatment. These data suggest t...